Nicollet Mall

CymaBay Announces Pricing of Upsized $225 Million Public Offering of Common Stock and Pre-Funded Warrants

Retrieved on:

Tuesday, September 12, 2023

Exercise, Attention, The Women on the 6th Floor, Capital market, Telephone, Sale, Prospectus, Liver, Conditional sentence, Nicollet Mall, Security (finance), Syndicate, Therapy

CymaBay is selling 12,551,080 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 583,771 shares of common stock in the offering.

Key Points:

CymaBay is selling 12,551,080 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 583,771 shares of common stock in the offering.
The shares of common stock are being sold at a public offering price of $17.13 per share, and the pre-funded warrants are being sold at a public offering price of $17.1299 per underlying share.
The gross offering proceeds to CymaBay from this offering are expected to be approximately $225 million, before deducting the underwriting discount and other estimated offering expenses, and excluding the exercise of any pre-funded warrants.
All shares of common stock and pre-funded warrants to be sold in the offering are being offered by CymaBay.

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

Retrieved on:

Monday, September 11, 2023

Morgan Stanley, Attention, SVB Securities, Varick Street, Therapy, Telephone, Research, Sale, Prospectus, State Street, SAN, Security (finance), Nicollet Mall, 2nd Floor, Broadridge Financial Solutions

In addition, Crinetics intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of common stock.

Key Points:

In addition, Crinetics intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of common stock.
All of the shares to be sold in the offering are to be sold by Crinetics.
There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Crinetics intends to use the net proceeds from the proposed offering to fund the development of paltusotine, CRN04894 and its other research and development programs, and for working capital and general corporate purposes.

CymaBay Announces Proposed $150 Million Public Offering of Common Stock and Pre-Funded Warrants

Retrieved on:

Monday, September 11, 2023

Attention, The Women on the 6th Floor, Capital market, Telephone, Sale, Prospectus, Liver, Conditional sentence, Nicollet Mall, Security (finance), Syndicate, Therapy

All shares of common stock and pre-funded warrants to be sold in the offering will be offered by CymaBay.

Key Points:

All shares of common stock and pre-funded warrants to be sold in the offering will be offered by CymaBay.
CymaBay intends to grant the underwriters a 30-day option to purchase up to an aggregate of an additional 15% of the shares of its common stock offered in the public offering, including shares of common stock underlying the pre-funded warrants.
The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Piper Sandler, Raymond James, Cantor and LifeSci Capital are acting as the joint book-running managers for the offering.

Natera Announces Pricing of $250 Million Follow-On Offering

Retrieved on:

Thursday, September 7, 2023

Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the pricing of its underwritten public offering of 4,550,000 shares of its common stock at a price to the public of $55.00 per share.

Key Points:

Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the pricing of its underwritten public offering of 4,550,000 shares of its common stock at a price to the public of $55.00 per share.
Closing of the offering is expected to occur on September 11, 2023, subject to customary closing conditions.
In addition, Natera has granted the underwriters a 30-day option to purchase up to an additional 682,500 shares of its common stock at the public offering price less the underwriting discounts and commissions.
Morgan Stanley, Goldman Sachs & Co. LLC, TD Cowen and Piper Sandler are acting as joint book-running managers for the offering.

Natera Launches Proposed Follow-On Offering

Retrieved on:

Wednesday, September 6, 2023

Natera, Inc. (Nasdaq: NTRA) (“Natera”), a global leader in cell-free DNA (cfDNA) testing, today announced the launch of a proposed follow-on public offering of $250,000,000 of shares of its common stock.

Key Points:

Natera, Inc. (Nasdaq: NTRA) (“Natera”), a global leader in cell-free DNA (cfDNA) testing, today announced the launch of a proposed follow-on public offering of $250,000,000 of shares of its common stock.
In addition, Natera expects to grant the underwriters a 30-day option to purchase up to an additional $37,500,000 of shares of its common stock at the public offering price less the underwriting discounts and commissions.
The offering is subject to market and other conditions.
Morgan Stanley, Goldman Sachs & Co. LLC, TD Cowen and Piper Sandler are acting as joint book-running managers for the offering.

Inaugural Zip Annual User Conference Will Equip Finance and Procurement Leaders to Successfully Navigate Economic Volatility

Retrieved on:

Wednesday, August 23, 2023

Zip , the world’s only intake-to-pay platform, today announced its inaugural annual user conference, Zip Forward, will be held November 8, 2023, in the heart of San Francisco’s Financial District at The Conservatory at One Sansome.

Key Points:

Zip , the world’s only intake-to-pay platform, today announced its inaugural annual user conference, Zip Forward, will be held November 8, 2023, in the heart of San Francisco’s Financial District at The Conservatory at One Sansome.
Distinguished finance and procurement executives, industry thought leaders and Zip customers will converge to explore the latest trends, advancements and real-world success stories of how designing for speed and user experience can enable them to control spend and thrive in times of economic volatility.
This conference is a timely and critical exchange for organizations aiming to empower their finance and procurement leaders.
“Zip uniquely addresses the root cause of the challenges procurement teams face by modernizing spend controls in a way that prioritizes user experience and increases adoption.”

Sagimet Biosciences Announces Closing of Underwriters’ Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering

Retrieved on:

Tuesday, August 15, 2023

Exercise, Attention, Lexington Avenue, Therapy, Telephone, Cyprus Securities and Exchange Commission, Sale, Prospectus, SAN, Security (finance), Nicollet Mall

All of the shares of Series A common stock sold in the initial public offering were offered by Sagimet.

Key Points:

All of the shares of Series A common stock sold in the initial public offering were offered by Sagimet.
After giving effect to the partial exercise of the underwriters’ option to purchase additional shares, Sagimet has issued a total of 6,026,772 Series A common stock in the initial public offering for aggregate gross proceeds of approximately $96.4 million, before deducting underwriting discounts and commissions and other offering expenses payable by Sagimet.
Goldman Sachs & Co. LLC, Cowen and Company, LLC and Piper Sandler & Co. acted as joint book-running managers for the offering.
Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on July 13, 2023.

PROCEPT BioRobotics Corporation Announces Pricing of Upsized Offering of Common Stock

Retrieved on:

Wednesday, August 2, 2023

Attention, Lexington Avenue, TD, Telephone, BofA Securities, Sale, Prospectus, Security (finance), Nicollet Mall, Health

REDWOOD CITY, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the pricing of an upsized underwritten public offering of 4,422,169 shares of its common stock at a public offering price of $33.92 per share, before underwriting discounts and commissions, for aggregate gross proceeds of approximately $150 million.

Key Points:

REDWOOD CITY, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the pricing of an upsized underwritten public offering of 4,422,169 shares of its common stock at a public offering price of $33.92 per share, before underwriting discounts and commissions, for aggregate gross proceeds of approximately $150 million.
In addition, PROCEPT BioRobotics has granted the underwriters a 30-day option to purchase up to an additional 663,325 shares of its common stock at the public offering price, less underwriting discounts and commissions.
All of the shares in the offering are to be sold by PROCEPT BioRobotics.
The offering is expected to close on or about August 4, 2023, subject to customary closing conditions.

PROCEPT BioRobotics Corporation Announces Proposed Offering of Common Stock

Retrieved on:

Tuesday, August 1, 2023

Attention, Lexington Avenue, TD, Telephone, BofA Securities, Sale, Prospectus, Security (finance), Nicollet Mall, Health

REDWOOD CITY, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the commencement of an underwritten public offering of $125,000,000 of shares of its common stock.

Key Points:

REDWOOD CITY, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the commencement of an underwritten public offering of $125,000,000 of shares of its common stock.
PROCEPT BioRobotics also expects to grant the underwriters a 30-day option to purchase up to an additional $18,750,000 of shares of its common stock.
All of the shares in the proposed offering are to be sold by PROCEPT BioRobotics.
BofA Securities, Piper Sandler and TD Cowen are acting as joint book-running managers for the proposed offering.

Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock

Retrieved on:

Tuesday, August 1, 2023

Exercise, Attention, Lexington Avenue, Therapy, Health, TD, Telephone, BofA Securities, SEC filing, Sale, Needham & Company, Prospectus, S-3, Form, Security (finance), Nicollet Mall, Needham

The shares of common stock issued and sold in the public offering at the closing include 1,875,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less the underwriting discounts and commissions.

Key Points:

The shares of common stock issued and sold in the public offering at the closing include 1,875,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less the underwriting discounts and commissions.
All of the shares of common stock in the public offering were sold by Inozyme.
Inozyme received net proceeds of approximately $64.5 million from the offering, after deducting underwriting discounts and commissions and estimated offering expenses.
333-258702) relating to the shares of common stock offered in the public offering was filed with the Securities and Exchange Commission (the “SEC”) on August 11, 2021 and became effective on August 23, 2021.